On November 28, 2025, HC Wainwright & Co. maintained a Buy recommendation for Anavex Life Sciences (NasdaqGS:AVXL), predicting a notable upside potential of 778.85%. The average one-year price target is set at $33.66/share, with estimates ranging from $24.24 to $44.10, against the current closing price of $3.83/share.
Anavex Life Sciences is projected to achieve an annual revenue of $313 million, with a non-GAAP EPS forecast of $0.13. A total of 328 funds have reported holdings in the company, reflecting a 2.50% quarter-over-quarter increase, though total shares owned by institutions have shown a 0.50% decrease to 38,108K shares.
